Agencies, 22 June: Bharat Biotech’s Covaxin laga phase three trial te COVID-19 kelaaf protection te 77.8 percent efficacy toh dekhise. Etu khobor toh Tuesday te sources para janaishe. India te trials toh 25,800 manu khan ke loise aro result toh Drugs Controller General of India (DCGI) Subject Expert Committee para approved korise koise. Hyderabad-based Bharat Biotech toh dawai laga 3 trial data te janaidebole nemite questions hota te dekthari pai thakise koise.
Dawai toh Bharat Biotech para Indian Council of Medical Research (ICMR) logote melikena bona laga ase.
Bharat Biotech nemite major boost ase kelay koile World Health Organisation para Covid-19 vaccine Covaxin te Expression of Interest (EoI) te mana nemite aro pre-submission meeting toh June 23 te lobole schedule korise. Etu para dawai toh WHO emergency use listing (EUL) te osor howa thakibo/bonabo.
Add Comment